Hap Trading, LLC Spectrum Pharmaceuticals Inc Call Options Transaction History

Hap Trading, LLC

12 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 12, 2023	SELL	$0.38 - $1.07 $4,940 - $13,910	-13,000 Reduced 42.35%	17,700 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.52 $224 - $364	-700 Reduced 2.23%	30,700 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.43 - $1.56 $1,634 - $5,928	-3,800 Reduced 10.8%	31,400 $2,000
Q2 2022 Aug 12, 2022	BUY	$0.7 - $1.4 $12,530 - $25,060	17,900 Added 103.47%	35,200 $5,000
Q1 2022 May 12, 2022	BUY	$0.63 - $1.59 $10,899 - $27,507	17,300 New	17,300 $3,000
Q3 2021 Nov 10, 2021	SELL	$2.15 - $3.82 $37,840 - $67,232	-17,600 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$2.89 - $4.45 $4,913 - $7,565	1,700 Added 10.69%	17,600 $4,000
Q1 2021 May 14, 2021	BUY	$2.9 - $4.09 $5,510 - $7,771	1,900 Added 13.57%	15,900 $4,000
Q4 2020 Feb 16, 2021	SELL	$3.38 - $5.14 $30,758 - $46,774	-9,100 Reduced 39.39%	14,000 $2,000
Q3 2020 Nov 13, 2020	BUY	$2.99 - $4.9 $69,069 - $113,190	23,100 New	23,100 $11,000
Q1 2020 May 08, 2020	SELL	$1.83 - $3.45 $38,247 - $72,105	-20,900 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$3.5 - $10.35 $73,150 - $216,315	20,900 New	20,900 $1,000

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.